Skip to main content

Featured Section: Disease Biomarkers

The Disease Biomarkers section aims to bridge the identification and validation of discovered gene or protein-based, network or dynamic network biomarkers with human diseases, patient phenotypes, or clinical applications, and accelerate the development of human disease-specific biomarkers for the early diagnosis, monitoring, evaluation, and prediction of diseases. 

Edited by Xiangdong Wang, the section welcomes research on the development of advanced biotechnologies for biomarker discovery and development, identifying biomarkers associated with the early detection of diseases, monitoring of disease severity and duration as well as patient responses to therapies, prediction of patient outcomes and the evaluation, regulation and ethics of disease biomarkers.

Read the latest articles in the Disease Biomarkers section

Featured Research: The impact of heavy alcohol consumption on cognitive impairment in young old and middle old persons

Dementia indicates a significant disease burden worldwide with increased population aging. Cognitive impairment seems to be the prodrome of dementia. Identification of the factors modifying cognitive impairment and interventions may help to reduce the global burden of dementia. As most reports about alcohol drinking and cognitive impairment are derived from studies of middle aged adults, it is important to examine the effects of alcohol drinking on cognitive function in older adults. 

In this study, researchers aimed to investigate the impact of alcohol consumption on the risk of cognitive impairment in older adults. Findings demonstrated that light to heavy drinking was associated with lower risk of cognitive impairment in participants aged between 60 and 69 years, but caution is needed in the middle old people with heavy alcohol drinking.

Featured Review: Irritable bowel syndrome and microbiome - Switching from conventional diagnosis and therapies to personalized interventions

Gastrointestinal diseases are still one of the most prominent area of study in host-microbiome interactions. However the underlying microbial mechanisms in these disorders are not fully established. Irritable bowel syndrome (IBS) remains as one of the prominent disorders with significant changes in the gut microbiome composition and without definitive treatment. IBS has a severe impact on socio-economic and patient’s lifestyle. However, there are no clear evidence of potential treatment for IBS. 

In this review, researchers summarize the epidemiology and socioeconomic impact of IBS, and microbiome observational and clinical trials. A new perspective using data-driven approach and applying computational modelling and machine learning to design microbiome-aware personalized treatment for IBS is proposed.

Journal of Translational Medicine has launched In Review, a new option that provides authors with on-demand information on the status of their manuscript, enables them to share their work with funders and their research community, and allows their colleagues to comment and collaborate - all whilst their manuscript is under review.

Read More

Meet the Editors

Get to know the Editors behind Journal of Translational Medicine! 


  1. Authors: Alice Avian, Nicolò Clemente, Elisabetta Mauro, Erica Isidoro, Michela Di Napoli, Sandra Dudine, Anna Del Fabro, Stefano Morini, Tiziana Perin, Fabiola Giudici, Tamara Cammisuli, Nicola Foschi, Marco Mocenigo, Michele Montrone, Chiara Modena, Martina Polenghi…

Journal News

Please note that Journal of Translational Medicine is no longer considering submissions of study protocols. 

Thank you to the JTRM reviewers!

Journal of Translational Medicine would like to warmly thank the top reviewers whose comments helped to shape the journal, for their assistance with review of manuscripts in Volume 18 (2020). 

Our companion journal

Translational Medicine Communications. the companion journal to Journal of Translational Medicine, is an interdisciplinary forum for all scientifically valid research from across translational medicine. 

The journal aims to improve transparency and reproducibility within translational medicine and considers research papers regardless of outcome or significance of findings.

Explore Translational Medicine Communications

Introducing new sections to Journal of Translational Medicine!

Translational Signaling and System Biology

© © selvanegra / Getty Images / iStockLed by Section Editor Marcello Maggiolini, this exciting new section is dedicated to uncovering pivotal transduction signaling involved in pathophysiological processes toward a translational impact on the discovery of novel targets and therapeutics.

Translational Signaling and System Biology section welcomes articles providing new mechanistic insights on a broad range of fields, drug action through new formulations and delivery methods, novel cellular and animal models, computational and systems biology, and innovative laboratory concepts fostering translational research from the bench to the bedside.

Translational Craniofacial and Dental Medicine

Led by Section Editor Giuseppe Intini, this new section aims to foster new discoveries in the field of Craniofacial and Dental Medicine. It is interested in interested in research that investigates innovative approaches in all craniofacial and dental specialties, including oral medicine and oral pathology.

Translational Craniofacial and Dental Medicine will consider studies regarding therapeutic approaches for treatment of diseases and for tissue regeneration, biomaterials for restorative prosthesis and implantology, diagnostic tools, imaging, and large data analysis. Translational genomics and precision medicine studies that identify novel prognostic markers, tailored interventions, and prophylactic approaches are also welcome.

Immune RadioBiology

Led by Section Editor Claire Vanpouille-Box, this new section is interested in innovative research that investigate the crosstalk between ionizing radiations (IR), the tumor microenvironment (TME) and host immunity. 

Studies considered for publication include (but not limited to) those investigating the mechanisms of radiation-induced anti-tumor immune responses, the immune-stimulatory and immuno-suppressive properties of ionizing radiation from all sources, biomarkers predictive of immune response, immune escape mechanisms elicited by IR and radioresistance. Importantly, the section welcomes translational and clinical studies assessing the combination of IR with immunotherapies (IT) with an emphasis on clinical response and outcome.

Emerging Therapeutics

© Parilov / stock.adobe.comLed by Section Editor Gennaro Ciliberto, this exciting section is dedicated to the wave of emerging therapeutics arising from the intense research efforts and therapeutic breakthroughs based on recent scientific and technological developments.

Emerging Therapeutics is interested in original papers, reviews and perspectives on the advancements in the field, including genetic vaccines, monoclonal antibodies, CAR-Ts, gene therapy with viral vectors, clinical applications of CRISPR/CAS9 gene editing, microbiota-modulating approaches, ‘omics approaches, emerging therapeutics from the development of new technologies for drug development, and discovery of new intervention targets and the possibility for new drug combinations.

Editor-in-Chief: Francesco Marincola, Kite Pharma, USA

Dr. Marincola received his MD, summa cum laude from the University of Milan, Italy and Surgery training at Stanford University, California. His research interest lies in translational medicine and focuses on the development of strategies for the dynamic study of patients’ response to immunotherapy. His approach has brought seminal observations regarding the mechanisms leading to rejection of tumors, allograft rejection, graft-versus-host disease and autoimmunity.

Dr. Marincola is currently Global Head of Research at Kite Pharma, Santa Monica, California. He previously was President and Chief Scientific Officer at Refuge Biotechnologies, Menlo Park, California, Distinguished Research Fellow at AbbVie Corporation in Redwood City, California, Chief Research Officer at Sidra Medical and Research Center in Doha Qatar and Tenured Investigator at the National Institutes of Health, Bethesda Maryland. Dr. Marincola founded in 2003 the Journal of Translational Medicine of which he is currently the Editor-in-Chief. He is also Editor-in-Chief of Translational Medicine Communications. He is past-president of the Society for the Immunotherapy of Cancer (SITC) and of the International Society for Translational Medicine. Dr. Marincola is editor of several biomedical books including the SITC-affiliated Cancer Immunotherapy Principles and Practice Textbook. Dr. Marincola is an award winning fiction writer author of The Wise Men of Pizzo and the Cat Behind the Window.

Aims and scope

Journal of Translational Medicine is an open access journal publishing articles focusing on information derived from human experimentation so as to optimise the communication between basic and clinical science.

The journal covers all areas of translational medicine but also has several special sections:

Annual Journal Metrics